The US Food and Drug Administration (FDA) has granted approval for Tiziana Life Sciences’ investigational new drug (IND) to advance its Phase IIa study of intranasal foralumab intended to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results